TY - ADVS
T1 - CLL and COVID-19: Case Report of Use of Convalescent Plasma Plus Remdesivir
AU - Cutter, Noelle L
N1 - By: Noelle Cutter, PhD Posted: Wednesday, October 27, 2021 Due to the impairment of humoral responses in patients with chronic lymphocytic leukemia (CLL), there appears to be a higher risk of death from COVID-19.
PY - 2021/10/27
Y1 - 2021/10/27
N2 - Due to the impairment of humoral responses in patients with chronic lymphocytic leukemia (CLL), there appears to be a higher risk of death from COVID-19. Carla Schenker, MD, and colleagues from the University of Bern, Switzerland, described a patient with CLL and COVID-19 who experienced rapid clinical improvement followed by relapse after receiving convalescent plasma and the antiviral medication remdesivir. This case report was published in the British Journal of Haematology.
AB - Due to the impairment of humoral responses in patients with chronic lymphocytic leukemia (CLL), there appears to be a higher risk of death from COVID-19. Carla Schenker, MD, and colleagues from the University of Bern, Switzerland, described a patient with CLL and COVID-19 who experienced rapid clinical improvement followed by relapse after receiving convalescent plasma and the antiviral medication remdesivir. This case report was published in the British Journal of Haematology.
UR - https://jnccn360.org/cll/medical-literature/case-report-of-use-of-convalescent-plasma-plus-remdesivir/
M3 - Web publication/site
ER -